CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs

NCT07172256 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma
HPV Positive Oropharyngeal Squamous Cell Carcinoma
New Diagnosis Tumor
Locally Advanced

Interventions

DRUG: CUE-101
DRUG: Pembrolizumab

Sponsor

Yale University

Collaborators

[object Object]
[object Object]